^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD39 inhibitor

    Related drugs:
    1d
    IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov)
    P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201
    14d
    ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Mar 2026 --> Sep 2027 | Trial primary completion date: Mar 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598
    1m
    TTX-030-003: Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (clinicaltrials.gov)
    P2, N=194, Completed, Trishula Therapeutics, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2027 --> Mar 2026 | Trial primary completion date: Feb 2027 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • budigalimab (ABBV-181) • eltivutabart (TTX-030)
    2ms
    A Study in Adults With Desmoid Tumors (clinicaltrials.gov)
    P2, N=50, Recruiting, Elpiscience (Suzhou) Biopharma, Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    A Study in Adults With Desmoid Tumors (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Elpiscience (Suzhou) Biopharma, Ltd.
    New P2 trial
    9ms
    ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Arcus Biosciences, Inc. | Recruiting --> Active, not recruiting | N=87 --> 40
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598
    10ms
    IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors. (PubMed, Cancer Res Commun)
    IPH5201 as monotherapy, or in combination with durvalumab, was well tolerated at pharmacologically active doses that induced reduction of intratumoral CD39 enzymatic activity and showed preliminary evidence for disease stabilization.
    Journal
    |
    ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    Imfinzi (durvalumab) • IPH5201
    10ms
    Harnessing CD39 inhibition to boost antitumor immunity with extracellular ATP. (PubMed, J Immunol)
    Using the coculture system, we generated the first transcriptional eATP signature developed on primary human myeloid cells and applied it to real-world datasets, illustrating a response to eATP that can be measured in human tumors. These studies provide a mechanistic rationale for CD39 inhibition to promote antitumor immunity via the enhancement of eATP-driven myeloid cell activation of T cells across a variety of tumor settings and eATP-generative modalities.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • GZMB (Granzyme B) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    10ms
    A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Elpiscience (Suzhou) Biopharma, Ltd. | Trial completion date: Sep 2025 --> Feb 2027 | Trial primary completion date: Jun 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    11ms
    ES014-IIT-01: A Study of ES014 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=15, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting | Initiation date: Aug 2024 --> Nov 2024
    Enrollment open • Trial initiation date
    12ms
    A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Elpiscience (Suzhou) Biopharma, Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    1year
    A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=8, Completed, Elpiscience Biopharma, Ltd. | Active, not recruiting --> Completed | N=60 --> 8
    Trial completion • Enrollment change